Given their favorable safety profile, ease of administration, and efficacy across diverse populations, SGLT2 inhibitors should be considered a key component of guideline-directed medical therapy for HF, irrespective of diabetic status. The gene discussed is SLC5A2; the disease is hydrops fetalis.